文献速递造血干细胞移植与细胞治疗

CD4 T细胞中磷酸化ERK1/2与异基因造血干细胞移植后急性GVHD相关

Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

急性GVHD发生与第30天CD4+ T细胞ERK1/2磷酸化相关(P < .001),且体外MEK抑制剂trametinib可抑制该磷酸化;GVHD好转时磷酸化下降。提示CD4+ T细胞ERK1/2磷酸化可能成为诊断GVHD的生物标志物。

要点

  • 急性GVHD发生与第30天CD4+ T细胞ERK1/2磷酸化相关(P < .001)。
  • ERK1/2磷酸化优先见于naive/central memory CD4+ T细胞。
  • GVHD好转时ERK1/2磷酸化下降,提示可动态监测。

核心结论

  • 外周血CD4+ T细胞ERK1/2磷酸化状态可能成为诊断人GVHD的未来生物标志物。
  • MEK抑制剂对人类GVHD可能具有潜在疗效。

研究设计与样本

  • 纵向采集20例异基因造血干细胞移植受者外周血:1例骨髓移植、7例外周血干细胞移植、12例脐血移植。

主要发现

  • 急性GVHD发生与第30天CD4+ T细胞ERK1/2磷酸化相关(P < .001)。
  • 该磷酸化可被体外临床可达到浓度的MEK抑制剂trametinib抑制。
  • ERK1/2优先在naive/central memory CD4+ T细胞中磷酸化。
  • GVHD好转时ERK1/2磷酸化下降。

临床怎么用

  • 可考虑监测外周血CD4+ T细胞ERK1/2磷酸化作为GVHD诊断的辅助标志物。
  • MEK抑制剂对GVHD的潜在疗效尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To diagnose graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is sometimes difficult. We showed previously that MEK inhibitors selectively suppress murine GVHD while retaining antiviral and antitumor immunity. Here, we asked whether the RAS/MEK/ERK pathway is activated in human allo-HSCT recipients with GVHD, and whether the phosphorylated ERK1/2 can be a biomarker of GVHD. Peripheral blood was sequentially collected from 20 allo-HSCT recipients: 1 bone marrow transplant, 7 peripheral blood stem cell transplants (PBSCT), and 12 cord blood transplants. Ten of the 20 allo-HSCT recipients developed GVHD, and phosphorylation of ERK1/2 in T and B cells was analyzed by flow cytometry. Occurrence of acute GVHD was associated with phosphorylation of ERK1/2 in CD4+ T cells at day 30 (P < .001), which was suppressed by ex vivo exposure to a MEK inhibitor trametinib at clinically achievable concentrations. In particular, ERK1/2 was phosphorylated preferentially in naive/central memory CD4+ T cells. Notably, phosphorylation of ERK1/2 fell as GVHD improved. These results suggest that phosphorylation status of ERK1/2 in peripheral blood CD4+ T cells may be a future biomarker for diagnosing human GVHD, and the potential efficacy of MEK inhibitors against human GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Itamura H, Shindo T, Yoshioka S, et al. Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2020. PMID: 32078679. doi:10.1182/bloodadvances.2019000343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。